← Search & browse all drugs
CARDIOVASCULAR SYSTEM › LIPID MODIFYING AGENTS › LIPID MODIFYING AGENTS, PLAIN › Other lipid modifying agents
inclisiran
C10AX16
Forms & Strengths
- Subcutaneous solution: 284 mg/1.5 mL in a single-dose pre-filled syringe
Adult Dosing
- 284 mg subcutaneously initially, again at 3 months, then every 6 months thereafter
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
Indications
- Adjunct to diet and maximally tolerated statin therapy for treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease requiring additional lowering of LDL-C
Mechanism of Action
- Small interfering RNA (siRNA) directed against PCSK9 mRNA; utilizes RNA interference to hepically reduce synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9), thereby increasing LDL receptor recycling and clearance of LDL-C from blood
Contraindications
- History of hypersensitivity to inclisiran or any of its excipients
Adverse Reactions
- Injection site reactions (pain, redness, rash)
- Arthralgia
- Urinary tract infection
- Diarrhea
- Bronchitis
- Pain in extremity
- Dyspnea
Drug Interactions
- No formal clinical drug-drug interaction studies conducted
- Not a substrate, inhibitor, or inducer of cytochrome P450 enzymes
- Not a substrate for major drug transporters
Curated Content: Needs Vetting Before Put to Clinical Use